Many of the key decisions in lymphocyte differentiation
Introduction
Immunoglobulin (Ig) gene transcription is specific to B lymphocytes and is regulated by B-cell specific promoter and enhancer elements (Staudt and Lenardo, 1991; Ernst and Smale, 1995) . The activity that confers cell-specific promoter function was first identified biochemically as the B-cell specific coactivator OCA-B (Luo et al., 1992) . OCA-B interacts with the octamer-binding family of transcription factors, Oct 1 and Oct 2, and together with either of these DNA-binding activators mediates efficient cell type-specific transcription of Ig promoters both in vitro and in transfected tissue culture cells (Luo et al., 1992; Gstaiger et al., 1995; Luo and Roeder, 1995; Strubin et al., 1995) . Biochemical purification and molecular cloning 5066 © Oxford University Press revealed that OCA-B consists of a single proline-rich polypeptide with sequence homology to other coactivators (Luo and Roeder, 1995) . Human cDNAs encoding the same protein (designated as OBF-1 or Bob-1) were cloned independently by yeast one-hybrid screens for factors that coactivate Oct 1 and Oct 2 (Gstaiger et al., 1995; Strubin et al., 1995) .
OCA-B-enhanced transcription is dependent upon either Oct 1 or Oct 2 but appears to be restricted to Ig promoters, since OCA-B has no significant effects on transcription of other (e.g. histone H2B) octamer-containing and Oct 1-dependent promoters (Luo et al., 1992; Luo and Roeder, 1995) . OCA-B alone does not bind specifically to DNA, but instead is recruited to the octamer sites of Ig promoters by direct interaction with the DNA recognition (POU) domain of Oct 1 or Oct 2 (Gstaiger et al., 1995; Luo and Roeder 1995; Pfisterer et al., 1995; Strubin et al., 1995) . The binary complex of the octamer-binding activator Oct 1 (or Oct 2) and the coactivator OCA-B is thought to activate transcription initiation by specific interactions with the TATA-box-associated basal transcription machinery (Luo and Roeder, 1995; Schubart et al., 1996b) . Promoter selectivity is believed to be a complex function of promoter element and basal transcription machinery topology (Luo and Roeder, 1995) .
Surveys of a large number of human and murine cell lines indicated that OCA-B mRNA is expressed primarily by cells of B lymphoid origin. High constitutive levels of OCA-B expression were found in transformed cell lines representing all stages of B lymphocyte development, including pro-B, pre-B, mature B and plasma cell stages (Gstaiger et al., 1995; Luo and Roeder, 1995; Strubin et al., 1995; Schubart et al., 1996b) . The only known exceptions are Jurkat T cells and immature thymocytes that were found to express OCA-B transiently after stimulation with a combination of phorbol 12-myristate 13-acetate (PMA) and ionomycin (Zwilling et al., 1997) . However, the physiological significance of induced expression in Jurkat cells and thymocytes was not clear (Zwilling et al., 1997) .
Based on in vitro and in vivo functional assays and the pattern of expression in cell lines, it was expected that disruption of the OCA-B gene would impair both B cell development and Ig transcription. Somewhat surprisingly, however, OCA-B -/-mice showed no defect in either early B cell differentiation or IgM production. Instead, the two most prominent features of the mutant phenotype were the absence of germinal centers (GCs) and a profound deficiency in serum Igs of secondary isotypes (Kim et al., 1996; Nielsen et al., 1996; Schubart et al., 1996a) . Similar phenotypes have also been reported in CD40L (Renshaw et al., 1994; Xu et al., 1994) , CD40 (Kawabe et al., 1994) , CD19 (Engel et al., 1995; Rickert et al., 1995) , CR2/ CD21 (Ahearn et al., 1996) , interleukin receptor common γ chain (γ c ) (Cao et al., 1995; DiSanto et al., 1995) and CD28 (Ferguson et al., 1996) mutant mice and humans. However, there is no known link between OCA-B and the B-cell antigen receptor (BCR), interleukin receptor or CD40 pathways, and no understanding of how these signals might be integrated in B cells undergoing the GC reaction.
Here we report that the absence of GCs in OCA-B -/-mice may be explained by the finding that signals essential for GC formation, including those produced by the BCR, CD40, and IL 4R, are integrated to induce OCA-B expression specifically in GC cells in vivo.
Results

OCA-B is only essential for the GC pathway of B cell differentiation
To determine whether the absence of GCs in OCA-B -/-mice was due to alterations in lymphoid microarchitecture, we stained spleen sections with anti-IgM and anti-IgD. We found no reproducible differences either in the primary follicle (IgM ϩ IgD ϩ double positive cells) or in the marginal zone (IgM high IgD low cells) between OCA-B -/-and control mice (Figure 1 , top and middle panels). Primary B cell follicles in OCA-B -/-mice also displayed a normal number and distribution of follicular dendritic cells, as determined with anti-CR1 monoclonal antibody 8C12 (Kinoshita et al., 1988) (Figure 1, bottom panel) .
There are two pathways of B cell differentiation after immunization with T-dependent antigens (MacLennan, 1994; Nossal, 1994; Kelsoe, 1996) . Activated B cells form pauciclonal aggregates which either become plasmacytes or translocate to the follicular area to develop into GC cells (Jacob et al., 1991; Liu et al., 1991; Lalor et al., 1992) . To determine which step in T-dependent immune (-/-) littermates that had been immunized with NP-CGG for 3 days were stained with either CGG (blue, ϫ60), CGG ϩ anti-IgM (CGG/IgM, blue and red, respectively, ϫ200 from T cell zone) or CGG ϩ anti-BrdU (CGG/BrdU, blue and red, ϫ200 from T cell zone). (B) Spleen sections from the animals that had been immunized with NP-CGG for 5 days were stained with CGG ϩ anti-IgM (CGG/IgM, blue and red, respectively, ϫ40) to show antigen-specific plasma cells in the T cell area and the red pulp. (C) Spleen sections from the animals that had been immunized with NP-CGG for 10 days were stained with CGG ϩ anti-IgM (CGG/IgM, blue and red, respectively, ϫ40) to reveal antigen-specific germinal centers. The T cell zone (T), B cell follicle (F), red pulp (RP), antigen-specific plasma cells (PC) and germinal center (GC) are indicated.
responses requires OCA-B, we immunized OCA-B -/-and control mice with nitrophenyl-acetyl chicken gamma globulin (NP-CGG) and followed antigen-specific B cell development in situ. We found that the initial proliferative expansion of antigen-specific B cells at day 3 to 6 was similar in OCA-B -/-mice and controls ( Figure 2A , top panel, only the day 3 data are shown). IgM-positive antigen-specific dividing B cells were found in small aggregates in the T cell zone in all samples (Figure 2A , second panel: IgM ϩ CGG ϩ , and third panel: CGG ϩ BrdU ϩ ). At day 5 to day 10, similar frequencies of antigen-specific plasmacyte foci were detected at the outer edge of the T cell zone adjacent to the red pulp area in both OCA-B -/-and control mice ( Figure 2B , day 5). However, follicular expansion of the antigen-activated B cells and formation of nascent GCs were completely absent in the mutant mice ( Figure 2C , day 10). Similar results were also obtained with spleens from mice immunized with trinitrophenyl-keyhole limpet hemocyanin (TNP-KLH) that were stained to reveal hapten-reactive B cells (not shown). We conclude that the absence of OCA-B does not affect either the initial response to antigen, primary B-cell follicle formation, marginal zone structure or plasma cell differentiation, but does block specifically GC development inside the follicle.
B-cell autonomous defect in GC development
To determine whether the absence of GCs and secondary isotype antibody responses in OCA-B -/-mice is T-or B-cell specific, we performed short-term reconstitution experiments using lymphocyte-deficient RAG-1 -/-mice as recipients of wild-type, OCA-B ϩ/-or OCA-B -/-B and T cells. Purified B and T cells were combined and injected into RAG-1 -/-mice, and a day after cell transfer the reconstituted animals were challenged with TNP-KLH. Spleens from the reconstituted animals were analyzed by immunohistochemistry, and sera were collected to measure specific antibody responses 14 days after antigen challenge. Results for wild-type and OCA-B ϩ/-T and B cells were identical, and only experiments with OCA-B ϩ/-cells are shown.
All mice reconstituted with T and B cells developed specific anti-TNP IgM responses (not shown), and showed similar numbers of anti-TNP-specific plasma cells in the red pulp of the spleen (Figure 3 , bottom panel, TNPalkaline phosphatase and anti-IgM staining). In addition, all combinations of B and T cells produced normal appearing lymphoid follicles with distinct T and B cell areas (Figure 3 , middle panel, anti-CD3 and anti-B220 staining). However, only those mice receiving wild-type 
OCA-B is expressed preferentially in GC B cells
The restricted nature of the OCA-B -/-phenotype was difficult to account for in view of the reported lack of regulated OCA-B expression in cell lines representing all stages of B cell differentiation (Gstaiger et al., 1995; Luo and Roeder, 1995; Strubin et al., 1995; Schubart et al., 1996b) . To determine where OCA-B is expressed in vivo, we performed immunohistochemical staining of peripheral lymphoid organs from naive and immunized mice with two different affinity-purified polyclonal rabbit antibodies to OCA-B ( Figure 5A ). In all experiments, OCA-B ϩ/ϩ and OCA-B ϩ/-mice were indistinguishable, and only the results for OCA-B ϩ/-are shown. In contrast to the broad distribution of OCA-B in transformed B cell lines (Gstaiger et al., 1995; Luo and Roeder, 1995; Strubin et al., 1995; Schubart et al., 1996b) , OCA-B expression in peripheral lymphoid tissues was restricted to a subset of B cells that were in the IgM-positive and CD3-negative compartments of the white pulp ( Figure 5A , bottom panels) and colocalized with GC-specific peanut agglutinin (PNA) staining ( Figure 5A , top and middle panels of the serial sections). OCA-B-expressing cells were seen throughout the GCs but were most prominent in what appeared to be GC dark zones that contain rapidly proliferating centroblasts ( Figure 5A ). We were unable to detect OCA-B staining in activated B cell blasts in the T cell zone or in plasmacytes in the red pulp. Neither OCA-B nor PNA staining was seen in the OCA-B -/-controls ( Figure 5A ).
To confirm the results of the immunohistology, spleen B cells from immunized mice were separated into high and low density populations, and OCA-B protein expression was measured by Western blotting. GC B cells differ from naive B cells in that they are activated and rapidly proliferating (MacLennan, 1994; Nossal, 1994; Kelsoe, 1996) . These cells are enriched in the low density B cell fractions after Percoll gradient centrifugation, whereas naive B cells are found in high density fractions. Anti-OCA-B antibodies (Luo and Roeder, 1995) recognize two protein bands of 34 and 35 kDa in both human and mouse B cells (Luo and Roeder, 1995; X.-F.Qin, unpublished) . The 35 kDa species is a post-translationally modified form of the 34 kDa protein, and the two isoforms are equally active in stimulating octamer-dependent transcription from Ig promoters (Luo and Roeder, 1995) . Consistent with the immunolocalization experiments, OCA-B was highly expressed in the low density activated B cell fraction but difficult to detect in high density resting B cells or T cell controls ( Figure 5B ). Similarly, OCA-B protein was abundant in FACS-sorted IgD -CD38 ϩ human tonsil GC B cells (Liu et al., 1995) but present at only low levels in IgD ϩ CD38 -naive B cells (not shown).
Like GC B cells, pre-B cells which have acquired a functional Ig H chain are rapidly dividing cells (Rolink and Melchers, 1993; Melchers et al., 1994) . To determine whether OCA-B is also expressed during early B cell development, we measured OCA-B protein expression in large dividing B220 ϩ IgM -pro-/pre-B cells and small resting B220 ϩ IgM ϩ maturing B populations (Melchers et al., 1994; Constantinescu and Schlissel, 1997) . Low levels of both 34 and 35 kDa OCA-B bands were detected in the purified bone marrow B cells ( Figure 6 , lanes 1-4). The level of OCA-B protein was 2-to 3-fold higher in the B220 ϩ IgM -pro-/pre-B populations than in the B220 ϩ IgM ϩ maturing B as measured by densitometry. When compared with activated spleen B cells (Figure 6 , lanes 6 and 7), the amounts of OCA-B present in the pro-/ pre-B cells was 10-15 times lower on a per cell basis. We conclude that low levels of OCA-B are expressed in bone marrow B cell precursors, although OCA-B is not essential for early B cell differentiation since B cell development and maturation are normal in OCA-B -/-mice (Kim et al., 1996; Nielsen et al., 1996; Schubart et al., 1996a) . 6 . OCA-B expression in early and late B cells. Bone marrow B cells from young C57/BL6 mice were sorted into large B220 ϩ IgM -(B220ϩIgM-) and small B220 ϩ IgM ϩ (B220ϩIgMϩ) populations (see Materials and methods). Samples prepared from two independent sortings were analyzed. High density (HD B), low density (LD B) and LPS-stimulated (day 3) splenic B cell samples were as described in Figures 5 and 7 . Western blotting was performed on SDS whole-cell lysates (see Materials and methods). Lysates made from 2ϫ10 5 cells were used for the bone marrow and HD B samples; whereas 5ϫ10 4 cells were used for LD B and LPS samples. β-Actin Western blotting was included as a control.
Taken together, B cells that express high levels of OCA-B are restricted to GCs, and this restricted pattern of OCA-B expression correlates with its functional requirement in a cell-autonomous manner for GC development in vivo.
Induction of OCA-B in mature B cells
Genetic experiments have shown that GC formation requires integration of BCR, CD40 and cytokine receptor signaling pathways (Kawabe et al., 1994; Xu et al., 1994; Cao et al., 1995; Rickert et al., 1995; Ahearn et al., 1996; Ferguson et al., 1996) . To determine whether OCA-B expression is regulated by these signals, we measured OCA-B expression in primary B cells stimulated with various activators. High levels of OCA-B mRNA and protein, comparable with those detected in many B cell lines, were induced in resting B cells by lipopolysaccharide (LPS), a polyclonal activator. Induction of mRNA and protein was first seen 12 h after stimulation, and progressively accumulated over a 7 day culture period (Figure 7A and B). Although the protein and mRNA induction follow a similar time course, the level of OCA-B protein induction is higher than that of its mRNA ( Figure 7A and B). Thus both transcriptional and translational processes are likely to be involved in OCA-B regulation. Consistent with the finding that the 35 kDa form of the OCA-B protein is derived from the 34 kDa form through post-translational modification (Luo and Roeder, 1995) , the induction and accumulation of the modified species appear to be slower than those of its precursor.
In contrast to LPS, individual physiological stimuli such as CD40L, BCR engagement (anti-μ cross-linking) and IL 4 induced only low levels of OCA-B expression ( Figure 7C ). During T-cell dependent immune responses in vivo, these stimuli are integrated to activate B cell differentiation. To determine whether OCA-B levels could be regulated coordinately by these physiological stimuli, we measured OCA-B expression in response to combinations of CD40L, anti-μ and IL 4 stimulation. High levels of OCA-B expression were seen with either CD40L ϩ IL 4, CD40L ϩ anti-μ or CD40L ϩ anti-μ ϩ IL 4 ( Figure 7C, lanes 8-10) , but not with anti-μ ϩ IL 4 5070 ( Figure 7C , lane 6), with a time course similar to that seen for LPS stimulation ( Figure 7C ; data not shown). The kinetics of OCA-B induction are consistent with the specificity of the anti-OCA-B antibody staining in lymphoid tissues. OCA-B expression was below the level of immunohistochemical detection in recently activated B cells that are found in the T area ( Figure 5A ). In contrast, high levels of anti-OCA-B staining were seen in GC B cells that develop several days after stimulation with antigen and T cell help ( Figure 5A ). We conclude that OCA-B expression can be modulated by a number of signaling pathways, each of which is essential for GC formation in vivo.
OCA-B knockout does not alter the expression of Bcl-3, Bcl-6 and Oct 2 Recent studies have shown that GC formation is also disrupted in Bcl-3 and Bcl-6 knockout mice (Dent et al., 1997; Franzoso et al., 1997; Fukuda et al., 1997; Schwarz et al., 1997) . In particular, Bcl-6 is found to be expressed preferentially in GC B cells and is required in a cellautonomous manner for GC development (Fukuda et al., 1997) . To determine whether the OCA-B mutation affects either Bcl-3 or Bcl-6 expression, we performed Western blotting experiments to measure Bcl-3 and Bcl-6 protein levels in OCA-B -/-splenic B cells that were stimulated with combinations of B cell activators. In the absence of OCA-B, neither baseline expression nor induction of Bcl-3 and Bcl-6 proteins was altered. A low level of Bcl-6 protein was detected in all the samples ( Figure 8) ; no apparent induction was observed with the treated cells (Figure 8, lanes 3-14) , which is consistent with the previous reports that Bcl-6 is not induced by LPS, antiIgM, CD40L, IL 4 or combinations of these signals (Allman et al., 1996; Fukuda et al., 1997) . In contrast, Bcl-3 was induced modestly by LPS, LPS ϩ IL 4, CD40L ϩ IL 4 and CD40L ϩ anti-μ ϩ IL 4 (Figure 8 , lanes 3-6, 9, 10, 13 and 14), but no induction was found with CD40L alone or CD40L ϩ anti-μ treatments (Figure 8, lanes 7, 8, 11 and 12) . In all conditions, the levels of Bcl-3 expression were equivalent in OCA-B -/-B cells and the wild-type controls. To examine whether the OCA-B mutation alters Oct 1 and Oct 2 protein levels, the Western blots were probed with anti-Oct 1 and anti-Oct 2 antibodies. Oct 1 protein was found to be slightly increased in all the stimulated B cell samples (Figure 8 , lanes 3-14), whereas Oct 2 was induced modestly by LPS, LPS ϩ IL 4, CD40L ϩ anti-μ and CD40L ϩ anti-μ ϩ IL 4 treatments (Figure 8 , lanes 3-6 and 11-14), but not CD40L or CD40L ϩ IL 4 treatments (Figure 8, lanes 7-10) . OCA-B -/-B cells were identical to the wild-type in terms of Oct 1 and Oct 2 expression under all conditions tested. Taken together, we conclude that OCA-B disruption does not affect the expression of either Bcl-3, Bcl-6 or Oct 2 which have been implicated in late B cell differentiation and GC development.
Regulation of OCA-B expression by v-Abl kinase in pre-B cells
The regulated expression of OCA-B in primary B cells contrasts with the observation that transformed cell lines representing all stages of B cell development contain high levels of OCA-B protein. To determine whether oncogenic transformation per se can activate OCA-B expression, we made use of a temperature-sensitive Abelson virus (tsAbl)-transformed pre-B cell line (Chen et al., 1994) . High levels of OCA-B were found in the 103/4 ts-Abl cells at the permissive temperature when v-Abl was active ( Figure 9A and B, lane 1). However, shifting the temperature to non-permissive conditions resulted in downregulation of OCA-B at both protein and RNA levels ( Figure 9A and B, lanes 2, 3 and 4). Further, when the cells were returned to the permissive temperature, OCA-B expression was largely restored ( Figure 9A and B, lane 5) . The v-Abl protein binds to and constitutively activates Jak-1 and Jak-3 kinases (Danial et al., 1995) . These kinases normally are activated by interleukin receptor common γ c crosslinking, and they in turn activate Stat-5 and Stat-6 (Darnell et al., 1994; Ihle, 1996) . To determine whether OCA-B is downstream of the γ c family of interleukin receptors in pre-B cells, we stimulated the 103/4 ts-Abl cells at the non-permissive temperature with either IL 4 or IL-7. Both IL-7 and IL 4 could partially restore OCA-B expression in the ts-Abl-transformed cells ( Figure 9A and B, lanes 6 and 7). Thus, both of these cytokines can induce OCA-B through the interleukin receptor common γ c and the Jak-STAT pathway.
Discussion
Taken together, our results reveal that expression of OCA-B is induced synergistically by signals emanating from the BCR, CD40 and IL 4 receptor. This results in a pattern of expression which is both GC B cell specific and consonant with a B cell-autonomous GC deficiency in OCA-B -/-mice.
T cell-dependent antibody responses are initiated in the T cell zone of the white pulp with a proliferative burst followed by B cell differentiation into either GC cells or short-lived plasma cells (MacLennan, 1994; Nossal, 1994; Kelsoe, 1996) . The GC pathway produces long-lived memory B cells that can produce high-affinity antibodies of secondary isotypes. In contrast, B cells that differentiate directly into plasmacytes tend to produce low-affinity primary IgM antibodies (MacLennan, 1994; Nossal, 1994; Kelsoe, 1996) . We and others have reported that inactivation of OCA-B in mice results in disruption of antigendependent immune responses and GC formation (MacLennan, 1994; Nossal, 1994; Kelsoe, 1996) . However, it was not clear from those studies whether the defects are B cell autonomous or whether other aspects of T-dependent B cell responses are also disrupted by the OCA-B mutation. In particular, the proliferative response to antigen, plasma cell differentiation, primary follicle formation and the establishment of marginal zone B cells were not examined (Kim et al., 1996; Nielsen et al., 1996; Schubart et al., 1996a) . The immunohistochemical experiments presented here suggest that OCA-B is essential only for the GC reaction, whereas other B cell responses are OCA-B independent. Thus, although GC and extrafollicular B cell differentiation pathways are both induced in response to antigen, these responses appear to be governed by different sets of transcription regulators. This notion is also supported by experiments with Bcl-6 -/-mice (Fukuda et al., 1997) . Bcl-6 differs from OCA-B in that it is a typical DNA-binding transcription factor that belongs to the Krüppel-type zinc finger family whereas OCA-B is a coactivator that does not bind to DNA directly. Nevertheless, like OCA-B -/-mice, Bcl-6 -/-mice have specific abnormalities in GC development (Dent et al., 1997; Fukuda et al., 1997) and the Bcl-6 protein is also expressed preferentially in GC B cells (Fukuda et al., 1997) . One of the important differences between the two mutations is that Bcl-6 is not induced by CD40L, antiIgM or interleukins (Figure 8 ) (Allman et al., 1996; Fukuda et al., 1997) , and the connection between Bcl-6 and the activation of the GC reaction remains obscure (Fukuda et al., 1997) . In contrast, OCA-B appears to be directly downstream of the B-cell signaling pathways that activate GC cell differentiation. Since Bcl-6 expression is not altered in OCA-B -/-B cells, it suggests that OCA-B and Bcl-6 are involved in different pathways.
How OCA-B is induced by CD40L, anti-IgM and interleukins remains unclear, but the observation that many signaling pathways converge on OCA-B is consistent with previous reports that all transformed B cells express this coactivator. The early cytoplasmic mediators activated by CD40L, anti-IgM and interleukins in B cells have been studied extensively, and the three pathways triggered by these receptors are for the most part distinct. Cross-linking the BCR activates src and syk family kinases as well as the ras pathway (Gold and DeFranco, 1994) . In contrast, the tumor necrosis factor receptor-associated factors (TRAFs) appear to be the early mediators of the CD40 signaling (Cheng et al., 1995; Rothe et al., 1995; Ishida et al., 1996) , while the Jaks and Stats are the primary transducers of IL 4 receptor signals (Darnell et al., 1994; Ihle, 1996) . Malignant transformation frequently involves deregulated expression or mutation in components of these same pathways. For example, OCA-B normally is induced through the Jak-STAT pathway by interleukins and, in Abl-transformed pre-B cells, the oncogenic v-Abl kinase constitutively activates Jak-1 and Jak-3 (Danial et al., 1995) leading to OCA-B induction. We propose that the disparity between the pattern of OCA-B expression in vivo and in tumor cell lines is the result of OCA-B induction by the oncogenes that immortalize B cells.
The problem of how the signals emanating from CD40, BCR and interleukin receptors are integrated to produce the GC reaction has not been resolved. OCA-B mRNA and protein expression peaks 72-96 h after B cell stimulation. Thus, OCA-B induction is a late response which is likely to be downstream of immediate early B cell activators like NF-κB, NF-AT and AP-1 (Gold and DeFranco, 1994) . The nuclear programs induced in activated B cells by these early mediators are diverse, and most B cell responses are not affected by the absence of OCA-B. For example, the proliferative responses to LPS and CD40 cross-linking, as well as isotype switching induced by IL 4 in vitro, are all normal in OCA-B -/-B cells (Kim et al., 1996) . Although it is still possible that these pathways are integrated by a single common cytoplasmic activator for the GC program, it seems more likely that integration of these signals is a nuclear event. Of the mediators activated by the CD40L, anti-IgM and interleukin pathways, the only one that has been associated with the GC reaction is the p52 subunit of the NF-κB family of transcription factors (Baeuerle and Baltimore, 1996; Baldwin, 1996) . p52 has been implicated in the GC reaction through its association with Bcl-3 (Bours et al., 1993) . Bcl-3 -/-mice resemble OCA-B -/-mice in that they have no GCs (Franzoso et al., 1997; Schwarz et al., 1997) , but the absence of GCs in Bcl-3 -/-mice differs from the OCA-B -/-phenotype in that it is not B cell autonomous (Franzoso et al., 1997) . In addition, neither baseline expression nor induction of Bcl-3 in B cells is affected by OCA-B disruption (Figure 8) . Thus, the GC defect in Bcl-3 -/-mice appears to be more closely related to that found in mice that are deficient in tumor necrosis factor-α (TNF-α), TNF receptor I, lymphotoxin α (LTα) or LTβ (De Togni et al., 1994; Le Hir et al., 1996; Matsumoto et al., 1996; Pasparakis et al., 1996) . In contrast to the OCA-B -/-mice, all of these mice display disrupted lymphoid microarchitecture and abnormal follicular dendritic cell networks (De Togni et al., 1994; Le Hir et al., 1996; Matsumoto et al., 1996; Pasparakis et al., 1996) . Furthermore, in adoptive transfer experiments, LTα-or Bcl-3-deficient B cells are able to produce GCs, and thus the GC deficiency in these mice is not B-cell autonomous (Matsumoto et al., 1996; Franzoso et al., 1997) .
Biochemical studies indicate that OCA-B enhances transcription through specific protein-protein interactions with Oct 1 or Oct 2. Oct 2 is expressed predominantly in B cells and, like OCA-B, is induced by several different B cell activators (Figure 8 ) (Corcoran and Karvelas, 1994) . Furthermore, the Oct 2 mutation also affects late B cell activation and terminal differentiation (Corcoran et al., 1993; Corcoran and Karvelas, 1994) , but the phenotypes of the OCA-B -/-and Oct 2 -/-mice are not identical. Oct 2 -/-mice show early post-natal lethality (Corcoran et al., 1993) and profound defects in T-cell-independent B cell activation (Corcoran and Karvelas, 1994) . For example, Oct 2 -/-B cells respond poorly to LPS and fail to differentiate into antibody-forming cells (Corcoran and Karvelas, 1994) . In contrast, OCA-B -/-B cells respond to LPS stimulation and produce normal appearing plasma cell foci (Kim et al., 1996) . Consistent with the finding that Oct 2 is involved in a distinct set of B cell processes (Corcoran et al., 1993; Feldhaus et al., 1993; Corcoran and Karvelas, 1994) , the pattern of Oct 2 induction by LPS, anti-μ, CD40L, IL 4 and their combinations differs from that of OCA-B. Furthermore, the basal and induced levels of Oct 2 expression are not affected by the disruption of the OCA-B gene (Figure 8 ). The more severe and pleiotropic phenotype of the Oct 2 knockout is consistent with the hierarchy of activator and coactivator in transcriptional regulation (Luo and Roeder, 1995) .
OCA-B is the prototype cell type-specific transcription coactivator, and thus belongs to a class of regulators that generally are thought to be constitutively expressed within the lineage of a given cell type (Gstaiger et al., 1995; Luo and Roeder, 1995; Pfisterer et al., 1995; Strubin et al., 1995; Schubart et al., 1996b) . The observation that OCA-B is inducible and found predominantly in GC B cells in vivo was unexpected. The only other indication that OCA-B might differ from other well-described coactivators in being inducible was the observation that some T cell lines and immature thymocytes can be activated to express OCA-B after stimulation with PMA and ionomycin (Zwilling et al., 1997) . However, since primary T cells do not appear to express OCA-B and since T cell development and helper T-cell function for antibody responses are completely normal in OCA-B mutant mice, the physiological significance of OCA-B induction with pharmacological agents is not clear. In conclusion, activation of OCA-B is a late nuclear response that reflects multiple signaling inputs. Irrespective of the site of GC signal integration, it is clear that OCA-B is induced synergistically by BCR, CD40 and IL 4R signals and that these pathways converge on OCA-B in B cells in a manner which is essential for the GC program. Therefore, coactivator OCA-B resembles conventional DNA-binding transcrip-tion factors in integrating signals that mediate cell fate decisions.
Materials and methods
Mice, antigens and immunizations
Matched littermates from OCA-B ϩ/-back crosses (F3 in C57/BL6 background) were used in all experiments. No difference was observed between wild-type and heterozygous mutant animals, and only the latter are shown. Mice were maintained in a specific pathogen-free facility. NP-CGG (15:1) was prepared by conjugating (4-hydroxy-3 nitrophenyl)acetyl succinimide ester (Genosys) to CGG (Sigma) as previously described (Lalor et al., 1992) , and TNP-KLH was prepared by conjugating 2,4,6-trinitrobenezene sulfonic acid (Sigma) to keyhole limpet hemocyanin (Sigma) as previously described (Liu et al., 1991) . Mice (three sets for each time point) were immunized at the age of 8-12 weeks with 100 mg of alum precipitate of NP-CGG or TNP-KLH given intraperitoneally.
Reconstitution of splenic B and T cells in Rag-1-deficient mice B and T cell reconstitution in Rag-1-deficient mice was performed as described (Fukuda et al., 1997) . B cells were purified from splenocytes of OCA-B ϩ/-and OCA-B -/-matched littermates by depleting non-B lineage cells with biotinylated Mac-1 monoclonal antibody (M1/70, Pharmingen) in conjunction with streptavidin-coated Dynal magnetic beads (SA-M280, Dynal), and with anti-mouse Thy1.2-coated Dynal magnetic beads [Mouse pan-T (Thy1.2), Dynal]. T cells from the same mice were purified using anti-mouse B220-coated Dynal magnetic beads [Mouse pan-B (B220), Dynal] instead of anti-mouse Thy1.2-coated beads. FACS analysis with B220 and IgM, or CD3 staining showed that the B cell preparations contained Ͼ93% B220 ϩ IgM ϩ cells and Ͻ1% contaminating CD3 ϩ T cells, while T cell preparations contained Ͼ95% CD3 ϩ cells and Ͻ1% contaminating B220 ϩ IgM ϩ B cells. The mixtures of the purified B and T cells (1.5ϫ10 7 each) from OCA-B ϩ/-and OCA-B -/-animals in four different combinations were injected intravenously into Rag-1-deficient mice. Three independent reconstitutions were performed for each of the B and T cell combinations. The reconstituted mice were challenged with 100 mg of alum precipitate of TNP-KLH given intraperitoneally 24 h after the transfer. The spleen and serum were harvested on day 14 post-immunization.
Immunohistochemistry
Serial spleen cryosections (5-6 μm) were prepared for immunohistochemical staining. Biotinylated PNA (Vector) was used to stain GC B cells and was revealed with either an ABC/alkaline phosphatase and AP/III kit (blue, Vector) or an ABC/peroxidase and DAB kit (brown, Vector) as indicated. Anti-IgM was a direct peroxidase-labeled goat antimouse IgG antibody (Sigma) and was developed with AEC (red, Vector) or DAB substrate (brown, Vector). Biotinylated anti-mouse CD3 (145-2C11, Pharmingen) was revealed with ABC/peroxidase and AEC or DAB substrate after TSA amplification (DuPont NEN). Biotinylated anti-mouse B220 (RA3-6B2, Pharmingen) was revealed with an ABC/ alkaline phosphatase and AP/III substrate kit (blue, Vector). TNPconjugated alkaline phosphatase was used to detect the hapten-specific B cells and was visualized with an AP/III substrate kit (blue, Vector), and biotin-labeled CGG was used as the probe to detect the antigenspecific B cells. The number of B cells reacting to the carrier CGG was consistent between the individuals of either heterozygous or homozygous knockout animals. For IgD staining, rat anti-mouse IgD (SBA-1, Southern Biotech) was used and detected with affinity-purified biotinylated rabbit anti-rat IgG antibody (Vector) in conjunction with an ABC/alkaline phosphatase and AP/III substrate kit (blue, Vector). Anti-CR1 (8C12, Pharmingen) was a biotinylated antibody and was visualized with an ABC/alkaline phosphatase and AP/III substrate kit (blue, Vector). In vivo bromodeoxyuridine (BrdU) pulse-labeling and detection were performed as described (Toellner et al., 1996) . Mouse anti-BrdU (BU20a, Dako) was used as the first reagent and revealed with biotinylated rat anti-mouse IgG1 (G1-6.5, Pharmingen) and ABC/alkaline phosphatase.
Anti-OCA-B antibodies were affinity purified from rabbit antisera raised against the 172-256 region of OCA-B (Luo and Roeder 1995) or a 237-256 peptide [Bob1 (C20) from Santa Cruz], and biotinylated using Sulfo-NHS-LC-Biotin (Pierce). The biotinylated antibodies were revealed with avidin/alkaline phosphatase reagent and an AP-III substrate kit (blue, Vector). Identical GC-specific staining patterns were obtained with both anti-OCA-B antibodies. Normal rabbit sera as well as purified rabbit IgGs were used as controls.
Antibody assays
Anti-TNP antibody levels were measured by enzyme-linked immunosorbent assay (ELISA). Titers of total mouse Ig as well as the isotypespecific anti-TNP Igs were determined using plates coated with TNPconjugated bovine serum albumin (TNP-BSA), and biotinylated affinitypurified goat anti-mouse IgM, or goat anti-mouse IgG (Southern Biotech) and peroxidase-conjugated streptavidin (Vector) as the detecting reagents. Results are expressed as OD 405 absorbance values.
Cell purification
Splenocytes from female C57BL/6 mice (6-9 weeks old, Jackson Lab.) were depleted of red blood cells and subjected to 50-60-66-70% discontinuous Percoll gradient centrifugation. High density cells were collected at the interface of the 66-70% layers and low density cells were pooled from 50-60% and 60-66% layer fractions. T cells were removed by incubating with anti-mouse Thy1.2-coated magnetic beads [Mouse pan-T (Thy1.2), Dynal]. FACS analysis with B220 and IgM, or CD3 staining, showed that the high and low density B cell preparations were 90-93% pure. For T cell purification, unfractionated splenocytes were incubated directly with anti-mouse B220-coated magnetic beads [Mouse pan-B (B220), Dynal].
Bone marrow cells from female C57BL/6 mice (4-5 weeks old, Jackson Lab.) were stained with fluorescein isothiocyanate (FITC)-conjugated anti-mouse IgM (R6-60.2, Pharmingen) and phycoerythrin (PE)-conjugated anti-mouse B220 (RA3-6B2, Pharmingen). Large B220 ϩ/ IgM -and small B220 ϩ IgM ϩ B cells were sorted using a FACSVantage (Becton Dickinson).
Tissue culture
Purified high density resting B cells (2-3ϫ10 5 /ml) were cultured with RPMI 1640 (Gibco-BRL) supplemented with 10% fetal calf serum (Sigma), 2 mM L-glutamine, 0.1 mM MEM AA, 1 mM Na pyruvate, 10 mM HEPES 7.2 and 50 μM β-mercaptoethanol (Gibco-BRL). CD40L L cells were used as the source of CD40 ligand, and were maintained in the same medium supplemented with G418 (1 mg/ml) (Gibco-BRL) and 1ϫ HAT (Sigma) (Stuber et al., 1995) . CD40L stimulation was performed as previously described (Stuber et al., 1995) . Other reagents used for stimulation experiments were: LPS (Escherichia coli 0111:B4, Difco), 25 μg/ml; anti-μ, AffiniPure F(ab') 2 fragment of goat anti-mouse IgM (μ) (Jackson ImmunoResearch) 5 μg/ml; IL 4, mouse recombinant (Gibco-BRL), 5 ng/ml (50 U/ml); and IL-7, mouse recombinant (Genzyme), 15 ng (45 U)/ml. ts-Abl pre-B cell line 103/4 was grown in the RPMI 1640 medium with 1 mg/ml G418 (Gibco-BRL) at 34°C, 6% CO 2 as the permissive condition and at 39.5°C, 6% CO 2 as the nonpermissive condition (Chen et al., 1994) .
Protein and RNA analyses
For cells purified by cell sorting, SDS whole-cell lysates were used for Western blot analysis. The lysates were made by sonicating the cell pellet directly into 2ϫ SDS sample buffer (0.125 M Tris-HCl pH 6.8, 4% SDS, 1.14 M β-mercaptoethanol, 20% sucrose, 0.05% bromophenol blue) at 1ϫ10 6 cells/100 μl. Otherwise, Western blot analysis was performed on whole-cell extracts, which were made by multiple rounds of freeze-thaw of cells resuspended (at 2ϫ10 7 cells/100 μl) in 20 mM HEPES pH 7.9, 20% glycerol, 400 mM NaCl, 0.5 mM EDTA, 0.25 mM EGTA, 0.025% NP-40, 1 mM dithiothreitol (DTT), 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 0.5 mM NaF, 0.5 mM Na 3 VO 4 , 4 μg/ ml leupeptin, 4 μg/ml antipain and 1% aprotinin. Protein concentrations were determined with Bradford reagent (Bio-Rad) using BSA as a standard. Proteins were resolved on a 10% SDS-polyacrylamide gel, and transferred onto an Immobilon PVDF membrane (Millipore). The rabbit anti-OCA-B antisera (Luo and Roeder, 1995) , and affinity-purified rabbit polyclonal anti-Oct 1 (C-21, Santa Cruz), anti-Oct2 (C-20, Santa Cruz), anti-Bcl-3 (C-14, Santa Cruz), anti-Bcl-6 (C-19, Santa Cruz) and anti-β-actin (A2066, Sigma) antibodies were used for Western blot detection. The antigen-bound rabbit IgGs were visualized with a donkey anti-rabbit/horseradish peroxidase ECL system (Amersham) (Qin et al., 1994) . RNA preparation and Northern blotting were performed using a mouse full-length OCA-B cDNA as probe (Qin et al., 1994; Kim et al., 1996) .
